0001209191-19-030040.txt : 20190515
0001209191-19-030040.hdr.sgml : 20190515
20190515164225
ACCESSION NUMBER: 0001209191-19-030040
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190513
FILED AS OF DATE: 20190515
DATE AS OF CHANGE: 20190515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRASAD SUYASH
CENTRAL INDEX KEY: 0001679129
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37833
FILM NUMBER: 19829052
MAIL ADDRESS:
STREET 1: C/O AUDENTES THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY ST., SUITE 2650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Audentes Therapeutics, Inc.
CENTRAL INDEX KEY: 0001628738
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461606174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
BUSINESS PHONE: 415-638-6556
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-13
0
0001628738
Audentes Therapeutics, Inc.
BOLD
0001679129
PRASAD SUYASH
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO
CA
94108
0
1
0
0
Senior VP & Chief Med Officer
Common Stock
2019-05-13
4
M
0
10000
0.79
A
28236
D
Common Stock
2019-05-13
4
S
0
9946
36.9758
D
18290
D
Common Stock
2019-05-13
4
S
0
54
37.72
D
18236
D
Stock Option (right to buy)
0.79
2019-05-13
4
M
0
10000
0.00
D
2024-02-18
Common Stock
10000
30870
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote.
The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.
/s/ Thomas Soloway, as attorney-in-fact for Suyash Prasad
2019-05-15